Related Experiment Video

Updated: Apr 6, 2026

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
11:34

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

14.5K

Human Papillomavirus: Current and Future RNAi Therapeutic Strategies for Cervical Cancer

Hun Soon Jung1,2, Nirmal Rajasekaran3, Woong Ju4

  • 1Research Institute of Pharmaceutical Science, Department of Pharmacy, College of Pharmacy, Seoul National University, Seoul 151-742, Korea. hunsoonjung@abionbio.com.

Journal of Clinical Medicine
|August 5, 2015
PubMed

Insights

Human papillomaviruses (HPVs) can cause cancer. RNA interference (RNAi) therapies using small interfering RNAs (siRNAs) show promise for HPV-driven cancers, but require further validation for clinical use.

Area of Science:

  • Oncology
  • Virology
  • Molecular Biology

Background:

  • Human papillomaviruses (HPVs) are oncogenic DNA viruses linked to various cancers, notably cervical cancer.
  • HPV-associated carcinogenesis serves as a model for RNA interference (RNAi) cancer therapies due to the specific expression of viral oncogenes E6 and E7 in cancer cells.

Purpose of the Study:

  • To review current knowledge on HPV-associated carcinogenesis.
  • To explore the potential of RNAi, specifically small interfering RNAs (siRNAs), as a therapeutic strategy for HPV-driven cancers.
  • To assess promising therapeutic strategies combining siRNA with other treatments for clinical application.

Main Methods:

  • Review of existing literature on HPV, carcinogenesis, and RNAi therapeutics.
  • Analysis of siRNA-mediated gene silencing mechanisms and their application in cancer therapy.
  • Evaluation of challenges and future directions for siRNA-based cancer treatments.

Main Results:

  • RNAi, particularly siRNA technology, offers a versatile approach for targeting viral oncogenes like HPV's E6 and E7.
  • siRNA-based therapies have demonstrated potential in depleting single or multiple cellular and viral targets.
  • Further validation of in vitro and in vivo efficacy, off-target effects, and combination strategies is necessary.

Conclusions:

  • HPV-associated carcinogenesis is a viable model for developing RNAi-based cancer therapies.
  • siRNA technology holds significant promise for treating HPV-driven cancers and other diseases.
  • Optimizing siRNA delivery and combining it with conventional therapies are key to successful clinical translation.
Keywords:
HPV E6 and E7 oncogenescervical cancersiRNA pool

More Related Videos

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma10:26

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

Published on: March 11, 2014

28.4K
Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis06:57

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

11.5K

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
32
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
28.7K
RNA Interference01:23

RNA Interference

7.9K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
8.3K
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
1.4K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K